See the conference video at <www.lifesci.consortium.umn.edu/conferences/conferences.php> (last visited April 19, 2006); DusterT., “Lessons from History: Why Race and Ethnicity Have Played a Major Role in Biomedical Research.”Journal of Law, Medicine & Ethics34, no. 3 (2006): 487–496.
2.
See conference video, supra note 1; ChoM. K., “Racial and Ethnic Categories in Biomedical Research: There Is No Baby in the Bathwater,”Journal of Law, Medicine & Ethics34, no. 3 (2006): 497–499.
3.
CohnJ. N.JuliusS.NeutelJ.WeberM.TurlapatyP.ShenY.DongV.BatchelorA.GuoW., and LagastH., “Clinical Experience with Perindopril in African-American Hypertensive Patients: A Large United States Community Trial,”American Journal of Hypertension17 (2004): 134–38.
4.
See conference video, supra note 1; RobertsD. E., “Legal Constraints on the Use of Race in Biomedical Research: Toward a Social Justice Framework,”Journal of Law, Medicine & Ethics34, no. 3 (2006): 526–534.
5.
CohnJ. N., “Lumpers Versus Splitters,”Journal of Cardiac Failure6 (2000): 75–76.
6.
TaylorA. L.ZiescheS.YancyC.CarsonP.D'AgostinoR.Jr.FerdinandK.TaylorM.AdamsK.SabolinskiM., M. Worcel, and J. N. Cohn for the African-American Heart Failure Trial Investigators, “Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure,”New England Journal of Medicine351 (2004): 2049–57.
7.
YancyC. W., “Heart Failure in African-Americans: A Cardiovascular Enigma,”Journal of Cardiac Failure6 (2000): 183–86.
8.
CarsonP.ZiescheS., G. Johnson, and J. N. Cohn for the Vasodilator-Heart Failure Trial Study Group, “Racial Differences in Response to Therapy for Heart Failure: Analysis of the Vasodilator-Heart Failure Trials,”Journal of Cardiac Failure5 (1999): 178–87.
9.
See conference video, supra note 1; BlocheM. G., “Race, Money & Medicines,”Journal of Law, Medicine & Ethics34, no. 3 (2006): 555–558.
10.
CohnJ. N., “Evidence-Based Medicine: What Is the Evidence?”Journal of Cardiac Failure2 (1996): 159–61.
